Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

August 2018 - First Report Managed Care

Department

Conference Insider
08/30/2018
A pharmacist-led proactive therapeutic drug-monitoring program for patients taking Remicade (infliximab; Janssen) reduced costs and improved dose utility, according to research presented at Digestive Disease Week 2018.
A pharmacist-led proactive therapeutic drug-monitoring program for patients taking Remicade (infliximab; Janssen) reduced costs and improved dose utility, according to research presented at Digestive Disease Week 2018.
A pharmacist-led proactive...
08/30/2018
First Report Managed Care
Conference Insider
08/30/2018
According to a presentation at Digestive Disease Week 2018, use of intermittent intravenous proton pump inhibitors among patients with upper gastrointestinal bleeding was significantly cost-saving compared with continuous therapy. 
According to a presentation at Digestive Disease Week 2018, use of intermittent intravenous proton pump inhibitors among patients with upper gastrointestinal bleeding was significantly cost-saving compared with continuous therapy. 
According to a presentation at...
08/30/2018
First Report Managed Care
Conference Insider
08/30/2018
Patients often report cost-related insulin underuse that is commonly associated with poor glycemic control, according to research presented at the 2018 78th ADA Scientific Sessions. 
Patients often report cost-related insulin underuse that is commonly associated with poor glycemic control, according to research presented at the 2018 78th ADA Scientific Sessions. 
Patients often report...
08/30/2018
First Report Managed Care
Conference Insider
08/30/2018
In accordance with the American Diabetes Association (ADA) recommendations, researchers recently found that flash continuous glucose monitoring improved adherence and reduced acquisition costs when compared with self-monitoring of blood...
In accordance with the American Diabetes Association (ADA) recommendations, researchers recently found that flash continuous glucose monitoring improved adherence and reduced acquisition costs when compared with self-monitoring of blood...
In accordance with the American...
08/30/2018
First Report Managed Care
Conference Insider
08/30/2018
A recent systematic review, which was presented at the 2018 78th ADA Scientific Sessions, provided critical information for making evidence-based clinical and public health policy decisions.
A recent systematic review, which was presented at the 2018 78th ADA Scientific Sessions, provided critical information for making evidence-based clinical and public health policy decisions.
A recent systematic review,...
08/30/2018
First Report Managed Care
Conference Insider
08/30/2018
According to recent research, given the volatility in 340B and wholesale acquisition cost (WAC) pricing, a strategy for purchasing the most cost-effective national drug code (NDC) is complex and requires visibility to system purchase volume...
According to recent research, given the volatility in 340B and wholesale acquisition cost (WAC) pricing, a strategy for purchasing the most cost-effective national drug code (NDC) is complex and requires visibility to system purchase volume...
According to recent research,...
08/30/2018
First Report Managed Care
Conference Insider
08/30/2018
Inpatient administration of the cholesterol medication Zetia (ezetimibe; Merck) may be clinically warranted for only a small group of patients who are unresponsive or intolerant to statin therapy, according to research presented at the 2018...
Inpatient administration of the cholesterol medication Zetia (ezetimibe; Merck) may be clinically warranted for only a small group of patients who are unresponsive or intolerant to statin therapy, according to research presented at the 2018...
Inpatient administration of the...
08/30/2018
First Report Managed Care
08/30/2018

Paul Nicolaus

Paul Nicolaus
Payers are implementing a new strategy to counter the effects of drug manufacturer patient assistance programs. We take a closer look at these emerging copay accumulator programs and their potential ripple effect. 
Payers are implementing a new strategy to counter the effects of drug manufacturer patient assistance programs. We take a closer look at these emerging copay accumulator programs and their potential ripple effect. 
Payers are implementing a new...
08/30/2018
First Report Managed Care
08/30/2018

Jeff Craven

Jeff Craven
Gene therapy is a transformational treatment for some patients to potentially cure or prevent rare diseases. But questions still remain about how these drugs should be priced and who will pay for them.
Gene therapy is a transformational treatment for some patients to potentially cure or prevent rare diseases. But questions still remain about how these drugs should be priced and who will pay for them.
Gene therapy is a...
08/30/2018
First Report Managed Care

News

News
08/09/2018

Dean Celia

Dean Celia
Mary Barton, MD, MPP, vice president of performance at NCQA, explains how the process is becoming more aligned with real-world practice, what specific initiatives are being introduced or changed, and what organizations can start going now to...
Mary Barton, MD, MPP, vice president of performance at NCQA, explains how the process is becoming more aligned with real-world practice, what specific initiatives are being introduced or changed, and what organizations can start going now to...
Mary Barton, MD, MPP, vice...
08/09/2018
First Report Managed Care

Advertisement

Advertisement

Advertisement